[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"randomized-controlled-trial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:randomized-controlled-trial":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,46,79,118,165,192,216,248,271,294,322,348,381,407,431,459,489,515,541,563,623,652,683,707,732],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644018","the-effect-of-liposomal-bupivacaine-erector-spinae-plane-block-100644018",false,"NCT07667439","The Effect of Liposomal Bupivacaine Erector Spinae Plane Block","The Effect of Liposomal Bupivacaine Erector Spinae Plane Block on Postoperative Pain in Patients Undergoing Open Upper Abdominal Surgery: A Randomized, Controlled, Double-Blind Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective open upper abdominal surgery, including open liver, gastric and pancreatic surgery.\n2. Patients receiving general anesthesia with tracheal intubation.\n3. Aged from 18 to 80 years old.\n4. Patients with American Society of Anesthesiologists (ASA) physical status class Ⅰ-Ⅲ.\n5. Patients who can understand the trial content, are willing to strictly follow the clinical research protocol and complete the trial, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Patients complicated with severe primary diseases of the lung, liver, kidney, cardiovascular system and hematopoietic system.\n3. Bleeding tendency or coagulation dysfunction, defined as international normalized ratio (INR) ≥ 1.4, activated partial thromboplastin time \\> 38 s, or platelet count \\\u003C 80×10⁹\u002FL.\n4. Patients with aggravated cardiac diseases (complex congenital heart disease, heart failure and valvular disease) or pulmonary insufficiency.\n5. Skin infection at the puncture site for erector spinae plane block (ESPB).\n6. Previous history of neurological or psychiatric diseases, with inability to read, understand and communicate.\n7. Current obstructive or restrictive pulmonary disease.\n8. Patients with BMI greater than 30 kg\u002Fm².\n9. Drug abuse, long-term regular use of analgesics, or allergy to the study drugs.\n10. Patients who refuse to provide informed consent.\n11. Those enrolled in other randomized controlled trials simultaneously or with other conditions unsuitable for participation in this trial.","ALL","18 Years","80 Years",{"count":21,"type":22},148,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a single-center, randomized, controlled, double-blind clinical trial. A total of 148 patients undergoing elective open upper abdominal surgery will be included and randomly assigned 1:1 to receive ultrasound-guided erector spinae plane block with liposome bupivacaine plus bupivacaine hydrochloride or bupivacaine hydrochloride alone. The primary outcome is the AUC of resting pain scores from 0 to 72 hours postoperatively. This study aims to evaluate the analgesic efficacy and safety of liposome bupivacaine and provide a long-acting and safe postoperative analgesia strategy.",[28,29,30,31],"Liposome Bupivacaine","Erector Spinae Plane Block","Postoperative Analgesia","Randomized Controlled Trial",[28,29,30,31],"NOT_YET_RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-25","ACTUAL",{"date":39,"type":22},"2026-07-01",{"date":41,"type":22},"2027-02-05",{"name":43,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":70,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100623836","fascial-yoga-in-menopausal-women-100623836","NCT07401810","Fascial Yoga in Menopausal Women","The Effect of Fascial Yoga on Perceived Stress, Cognitive Control, and Cognitive Flexibility in Menopausal Women","FascialYogaM","Inclusion Criteria:\n\n* Female participants aged 45-65 years\n* In the menopausal period, defined as at least 12 months since the last menstrual period\n* Able to read and understand Turkish and to complete self-report questionnaires\n\nExclusion Criteria:\n\n* Current or past diagnosis of a psychiatric disorder or ongoing psychiatric treatment\n* Regular use of antidepressant, anxiolytic, or corticosteroid medications\n* History of cancer or currently receiving active oncological treatment\n* Participation in facial yoga or similar yoga-based programs within the past 6 months\n* Any medical condition that may prevent safe participation in mild physical activity\n* Incomplete attendance to intervention sessions or incomplete outcome data during the study period",true,"FEMALE","45 Years","65 Years",{"count":59,"type":22},100,[25],"Aim:\n\nThe aim of this study is to evaluate the effects of a structured fascial yoga-based behavioral intervention on perceived stress, cognitive control, and cognitive flexibility in menopausal women. The study aims to determine whether a non-pharmacological and non-invasive behavioral intervention can support psychological and cognitive functioning and reduce perceived stress in menopausal women.\n\nDesign:\n\nThis study is designed as a randomized controlled, pretest-posttest experimental study with a post-intervention follow-up assessment. Eligible participants will be randomly assigned to either the intervention group or the control group receiving usual care. Outcomes will be assessed at baseline, immediately after the intervention, and at follow-up to evaluate both the immediate and sustained effects of the intervention.\n\nMethod:\n\nA total of 100 menopausal women aged 45-65 years will be recruited from the menopause outpatient clinic and randomly assigned to either the intervention group or the control group. The intervention group will participate in a 12-week online fascial yoga program consisting of two 60-minute sessions per week.\n\nIn this study, fascial yoga is defined as a fascia-focused, non-pharmacological, and non-invasive behavioral intervention that includes myofascial release techniques, breath regulation, body awareness, and basic yoga practices to support stress regulation and cognitive functioning. The program will include myofascial release techniques, basic yoga postures suitable for all physical fitness levels, and structured breathing exercises. All sessions will be conducted online in a group format, and no audio or video recordings will be taken.\n\nThe control group will continue to receive routine outpatient care during the study period. After completion of the follow-up assessments, the fascial yoga program will be offered to participants in the control group upon request.\n\nData will be collected at three time points: at baseline before the intervention, immediately after completion of the 12-week intervention, and at the follow-up assessment 8 weeks after the intervention. Perceived stress, cognitive control, and cognitive flexibility will be assessed using validated self-report questionnaires.\n\nHypotheses:\n\nH1: Menopausal women participating in the fascial yoga intervention will show a significant reduction in perceived stress levels compared with the control group at post-intervention and follow-up assessments.\n\nH2: Menopausal women participating in the fascial yoga intervention will show a significant improvement in cognitive control and cognitive flexibility compared with the control group at post-intervention and follow-up assessments.",[63,64,65,66,31,67,68,69],"Menopause","Stress, Psychological","Cognitive Flexibility","Nonpharmacological Interventions","Cognitive Control","Perceived Stress","Yoga",[63,68,65,67,69],"2026-06-15",{"date":73,"type":37},"2026-06-17",{"date":39,"type":22},{"date":76,"type":22},"2027-06-01",{"name":78,"class":44},"Marmara University",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":45},"100610370","phase-3-suzetrigine-in-total-hip-arthroplasty-100610370","NCT07226700","Suzetrigine in Total Hip Arthroplasty","A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty","Inclusion Criteria:\n\n* Patients undergoing primary THA (posterior approach) with participating surgeons\n* Age 18 to 80 years old\n* Planned discharge to home\n* Planned use of neuraxial anesthesia\n* American Society of Anesthesiologists (ASA) Physical Status 1 - 3\n\nExclusion Criteria:\n\n* ASA greater than 3\n* Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)\n* History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)\n* History of QT prolongation\n* Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device\n* Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse\n* Inability to comply with any component of the study protocol\n* Younger than 18 or greater than 80 years old at the time of enrollment\n* Patient already on Suzetrigine\n* Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease\u002FChild Pugh B or C, use of strong CYP3 inhibitors or inducers)\n* Contraindications to neuraxial anesthesia or any other part of the study protocol\n* Participation in another investigational drug or device study\n* Pregnancy",{"count":87,"type":22},210,[89],"PHASE3","Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).",[92,93,94,95,96,97,98,99,100,101,102,103,104,105,31,106,107],"Total Hip Arthroplasty (THA)","Total Hip Arthroplasty \\(THA\\)","Total Hip Replacement","Total Hip Replacement Surgery","Total Hip Replacements","Total Hip Replacement Arthroplasty","Suzetrigine","Pain Management","Pain","Nav 1.8","JOURNAVX","Opioid Cessation","Opioid Consumption, Postoperative","Multimodal Analgesia","Randomized Controlled Study","Randomized Controlled Trials","RECRUITING","2026-06-02",{"date":111,"type":37},"2026-06-03",{"date":113,"type":37},"2025-11-03",{"date":115,"type":22},"2028-11-01",{"name":117,"class":44},"Hospital for Special Surgery, New York",{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":54,"sex":55,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":148,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100634052","early-pregnancy-lifestyle-and-glucose-patterns-a-substudy-of-tofffy-100634052","NCT07534670","Early Pregnancy Lifestyle and Glucose Patterns: A Substudy of TOFFFY","Early-Pregnancy Chronobehavioural Profiles and Continuous Glucose Dynamics: A Nested Randomised Pilot Study of TOFFFY","Inclusion Criteria:\n\n* Enrolled in the Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) (NCT06293235)\n* Females who are currently pregnant and with viable intrauterine pregnancy at ≤13 weeks gestation at enrolment\n\nExclusion Criteria:\n\n* Females with pre-existing diabetes mellitus (Type 1 or Type 2) and\u002For chronic medical conditions affecting glucose metabolism\n* Females who are taking medications known to significantly affect glucose metabolism\n* Females with multiple pregnancy (e.g., twins or higher-order gestation)\n* Females who are unable to comply with study procedures, including: Inability to use smartphone-based applications and inability to wear wrist actigraphy device","21 Years","39 Years",{"count":128,"type":22},140,[25],"The goal of this clinical trial is to examine how daily behavioral patterns in early pregnancy, including sleep, physical activity, and meal timing, influence continuous glucose dynamics and subsequent risk of gestational diabetes mellitus (GDM) in pregnant women without pre-existing diabetes.\n\nThe main questions it aims to answer are:\n\n1. Do early-pregnancy chronobehavioral patterns (e.g., irregular sleep, night eating, and unstable rest-activity rhythms) relate to continuous glucose patterns measured using continuous glucose monitoring (CGM)?\n2. Can early behavioral and CGM-derived measures predict glucose regulation and metabolic outcomes later in pregnancy (24-28 weeks)?\n3. Does real-time self-monitoring using wearable devices and food logging improve glycemic outcomes compared to usual care?\n\nThis study is a prospective, nested randomized pilot trial embedded within the ongoing Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) cohort (NCT06293235) at KK Women's and Children's Hospital, Singapore. A total of 140 pregnant women without pre-existing diabetes, recruited at ≤13 weeks gestation, will be randomized in a 1:1 ratio to either a pilot arm (wearable-based self-monitoring) or a control arm (usual care).\n\nParticipants in the pilot arm (n=70) will undergo intensive behavioral and metabolic monitoring over a 14-day period in early pregnancy, including continuous glucose monitoring using a CGM device, wrist actigraphy to assess sleep-wake and rest-activity patterns, and an AI-supported mobile application to record meal timing and dietary intake. Participants will have real-time access to their glucose data and behavioral feedback, enabling self-monitoring and potential behavioral adjustments.",[132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,31,147],"Continuous Glucose Monitoring","Diabetes, Gestational","Diet During Pregnancy","Meal Time","Actigraphy","Pregnancy","Glucose Intolerance During Pregnancy","Gestational Diabetes Mellitus in Pregnancy","Circadian Rhythm","Sleep","Chronobiology","Wearable Electronic Devices","Mobile Applications","Blood Glucose Profile","Metabolic Diseases","Pilot Study",[149,150,151,152,153,154],"Risk factor","Lifestyle","Early pregnancy","Chrono-disruptive behaviours","Maternal health","Lifestyle intervention","2026-04-22",{"date":157,"type":37},"2026-04-27",{"date":159,"type":22},"2026-05-01",{"date":161,"type":22},"2027-06-30",{"name":163,"class":164},"KK Women's and Children's Hospital","OTHER_GOV",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":55,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":45},"100621955","cheer-oral-health-in-pregnancy-study-100621955","NCT07377344","CHEER Oral Health in Pregnancy Study","Closing Health Equity Through Empowering Oral Health for Maternal Wellness","CHEER","Inclusion Criteria:\n\n1. Pregnant individuals aged 18 years or older with indications of periodontal diseases (gingivitis or mild periodontitis, moderate to severe periodontitis)\n2. Less than 20 weeks pregnancy at time of enrollment\n3. Has dental insurance (Medi-Cal or private coverage)\n4. Willing and able to provide informed consent\n5. Planning to receive ongoing prenatal care at study-affiliated clinics\n6. Access to a mobile phone for receiving text messages\n\nExclusion Criteria:\n\n1. Presence of systemic diseases or medical conditions that require antibiotic prophylaxis for dental procedures\n2. Current immunosuppressive therapy\u002Fuse of anti-inflammatory medications\n3. Receipt of active periodontal treatment within the past 6 months\n4. Complete edentulism (no natural teeth)\n5. Unable to read and write English\n6. Less than 9th grade education\n7. Enrollment in another oral interventional study",{"count":174,"type":22},160,[25],"Many pregnant people don't get the dental care they need, even though it's safe and important. The CHEER Study offers free dental check-ups, cleanings, and supplies to help participants take care of their teeth and gums during pregnancy. The purpose of this research study is to compare two types of noninvasive oral health interventions to evaluate their effectiveness. We want to learn if one method is more effective in supporting oral health and improving pregnancy outcomes. There are two aims of this study:\n\nAim 1: To evaluate whether a structured oral health intervention reduces periodontal inflammation during pregnancy and postpartum in pregnant people with indicators of periodontal disease.\n\nAim 2: To assess whether a structured oral health intervention is associated with changes in oral health behaviors or birth outcomes in pregnant people with periodontal disease.",[178,179,137,180,31,181,182],"Gingivitis","Dental Health","Pregnancy Outcomes","Periodontal Disease","Gum Disease","2026-04-01",{"date":185,"type":37},"2026-04-07",{"date":187,"type":22},"2026-06-01",{"date":189,"type":22},"2028-06-01",{"name":191,"class":44},"University of California, San Francisco",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":54,"sex":55,"minAge":18,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":45},"100416066","effect-of-hyaluronan-enriched-medium-on-the-cumulative-ongoing-pregnancy-rate-100416066","NCT04697823","Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate.","Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate: a Prospective Randomized Trial","TETHER","Inclusion Criteria:\n\n* Patients with own oocytes\u002Fembryos;\n* Patients with female age at 1st OR in the study \\\u003C40 year;\n* Patients planned for a 2nd oocyte retrieval, with no clinical ongoing pregnancy after the previous oocyte retrieval\n* Patients planned for a 3rd oocyte retrieval with no clinical ongoing pregnancy after previous oocyte retrievals\n* Patients with female age at 1st OR in the study \\\u003C40 year;\n* Patients with BMI ≤32;\n* Patients with written informed consent;\n\nExclusion Criteria:\n\n\\-","40 Years",{"count":202,"type":22},400,[25],"Assessing whether the use of hyaluronan-enriched transfer medium can increase the cumulative ongoing pregnancy rate",[206,31],"Hyaluronan-EnRiched Medium","2026-03-25",{"date":209,"type":37},"2026-03-30",{"date":211,"type":37},"2021-01-01",{"date":213,"type":22},"2026-12-31",{"name":215,"class":44},"KU Leuven",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":222,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":234,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":45},"100628425","effects-of-continuous-monitoring-and-progressive-regulation-of-inflatable-laryngeal-mask-airway-cuff-pressure-on-postoperative-pharyngolaryngeal-complications-in-elderly-patients-100628425","NCT07461467","Effects of Continuous Monitoring and Progressive Regulation of Inflatable Laryngeal Mask Airway Cuff Pressure on Postoperative Pharyngolaryngeal Complications in Elderly Patients","Inclusion Criteria:\n\n* Aged ≥ 60years;\n* Non-cardiac, non-thoracic, and non-head and neck surgery;\n* Non-laparoscopic surgery;\n* Elective surgery;\n* Surgical position: supine position ;\n* American Society of Anesthesiologists (ASA) physical status classification Ⅰ-Ⅲ;\n* New York Heart Association (NYHA) cardiac function classification Ⅰ-Ⅱ;\n* Expected surgical duration ≥30 minutes and ≤ 2 hours;\n* Body mass index (BMI) 18.5-30.0 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Preoperative predictable difficult airways, such as trismus, limited neck mobility, and other related conditions;\n* Preoperative pharyngeal and laryngeal complications including sore throat, hoarseness, blood-tinged sputum, and dysphagia;\n* Preexisting conditions such as loose teeth, laryngeal obstruction, laryngeal edema, acute airway inflammation, and gastrointestinal bleeding;\n* Comorbidities of respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma;\n* Allergies to ILMA materials (e.g., silicone, polyvinylchloride \\[PVC\\]);\n* Inability to cooperate with the study for any reason;\n* Participation in other clinical trials within 3 months prior to enrollment in this study;\n* Any other circumstances deemed inappropriate for inclusion by the investigators.","60 Years",{"count":224,"type":22},146,[25],"Currently, research on laryngeal mask airway (LMA) has been continuously deepened both domestically and internationally, which has greatly promoted the optimization process of clinical application and related management strategies. Numerous domestic and foreign research findings have consistently emphasized the key role of LMA cuff pressure monitoring in reducing postoperative complications, especially in alleviating sore throat and dysphagia. Foreign studies have extensively covered the research and development innovation of LMA devices, as well as comprehensive comparative analyses with other airway management methods such as endotracheal intubation, providing rich perspectives for expanding the application of LMA and improving its application effects. In contrast, domestic studies have distinct pertinence, focusing on application exploration in specific populations and clinical practice scenarios, and have provided important evidence for the safe and effective use of LMA in specific groups through in-depth research. However, it is undeniable that there are obvious deficiencies in both domestic and foreign research regarding the application of continuous monitoring and progressive regulation of LMA cuff pressure in elderly patients-a crucial field. Due to the natural decline of physiological functions, elderly patients face an increased risk of complications such as pulmonary and extrapulmonary complications, as well as pharyngolaryngeal complications, when using LMA during the perioperative period. Therefore, it is particularly urgent to carry out continuous pressure monitoring and progressive regulation of LMA cuff pressure, and to further explore the optimal range of LMA cuff pressure. This study will not only fill the current research gap but also provide solid support for the safe and efficient airway management of elderly patients during the perioperative period.",[228,229,31,230,231,232,233],"Elderly (People Aged 65 or More)","LMA","Laryngeal Mask Airways","Pharyngolaryngeal Postoperative Pain","Cuff Pressure","Oropharyngeal Leak Pressure",[235,236,237,238,31],"Elderly people","Laryngeal mask airways","pharyngolaryngeal complications","cuff pressure","2026-03-06",{"date":241,"type":37},"2026-03-10",{"date":243,"type":37},"2025-11-02",{"date":245,"type":22},"2027-03-01",{"name":247,"class":44},"First Affiliated Hospital of Chongqing Medical University",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":45},"100599858","patient-perception-of-physicians-compassion-communication-skills-and-professionalism-during-clinic-visits-a-randomized-controlled-trial-ehr-study-3-100599858","NCT07089953","Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3)","Eligibility Criteria\n\n1. Participants with a diagnosis of cancer either early disease or advanced cancer defined as locally advanced, recurrent, or metastatic disease.\n2. Outparticipants (either new referrals or follow-ups) seen in the Supportive Care Clinic.\n3. Age \\>\u002F= 18 years old.\n4. Able to read, write, and speak English.\n5. Participants with normal cognitive status (Memorial Delirium Assessment Scale (MDAS) \\\u003C\u002F= 6\u002F30) who can understand the nature and purpose of the study and have the ability to complete the consent process.\n\nExclusion Criteria\n\n1. Participants who are experiencing severe symptom distress, including severe emotional distress, which may interfere with study participation. This will be measured by the Edmonton Symptom Assessment Scale (ESAS). Eligibility of participants with ESAS score \\>\u002F= 7 on any item will be determined by the principal investigator and\u002For attending physician who is caring for the patient during that visit.\n2. Participants with cognitive dysfunction (Memorial Delirium Assessment Scale (MDAS) \\>\u002F= 7\u002F30 will be excluded from the study.",{"count":255,"type":22},88,[25],"To learn about how patients view a doctor's compassion, communication skills, and professionalism based on whether the doctor uses the Electronic Health Record (EHR) during a visit with a patient.",[259,260,31,261],"Communication Skills","Professionalism","Perception","2026-02-24",{"date":264,"type":37},"2026-02-25",{"date":266,"type":22},"2026-07-15",{"date":268,"type":22},"2028-12-31",{"name":270,"class":44},"M.D. Anderson Cancer Center",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":45},"100622377","effectiveness-of-a-visual-feedback-exercise-program-following-lumbar-surgery-100622377","NCT07382830","Effectiveness of a Visual Feedback Exercise Program Following Lumbar Surgery","Efficacy of Laser Pointer-Guided Visual Feedback Stabilization Exercise Program After Lumbar Microdiscectomy Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* To be between 18 and 65 years of age\n* Patients who underwent lumbar microdiscectomy surgery\n* Individuals who are literate in Turkish\n\nExclusion Criteria:\n\n* Patients who have previously undergone lumbar disc herniation surgery\n* The surgical procedure involving fusion has been performed.\n* Having a body mass index above 30\n* Suspected or confirmed tumors in the lumbar spine and spinal canal\n* Severe heart failure and cerebrovascular accident\n* The presence of cauda equina syndrome and concomitant diseases of the lumbar spine\n* The presence of heart conditions, orthopedic contraindications, or systemic diseases that could prevent participation in the exercise program\n* Refusing to participate in the study",{"count":279,"type":22},42,[25],"The aim of this study is to compare the effectiveness of stabilization exercises performed with visual feedback guided by a laser pointer after lumbar microdiscectomy surgery with that of standard stabilization exercises. The study, planned as a randomized controlled trial, will include 42 individuals aged 18-65 who have undergone lumbar microdiscectomy. Participants will be divided into two groups: a control group and a laser-guided exercise group. Both groups will undergo supervised stabilization exercises 3 days a week for 8 weeks, starting from the 6th postoperative week. The outcome measures were defined as pain, disability, back awareness, trunk muscle endurance, reaction time, balance, function, and lumbar proprioception. The findings are expected to demonstrate the effectiveness of visual feedback-assisted stabilization exercises in postoperative rehabilitation and contribute to clinical practice.",[283,284,31],"Lumbar Microdiscectomy","Postoperative Rehabilitation","2026-01-25",{"date":287,"type":37},"2026-02-03",{"date":289,"type":37},"2026-01-16",{"date":291,"type":22},"2028-06-30",{"name":293,"class":44},"Suleyman Demirel University",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":45},"100615932","optical-motion-capture-assisted-ultrasound-for-pediatric-eswl-100615932","NCT07299032","Optical Motion Capture-Assisted Ultrasound for Pediatric ESWL","A Randomized Controlled Study on the Localization Efficiency of Optical Motion Capture-Assisted Ultrasound Pre-localization in Pediatric Extracorporeal Shock Wave Lithotripsy","Inclusion Criteria:\n\n* Pediatric patients aged 0 to 14 years with a confirmed diagnosis of upper urinary tract stones.\n* Diagnosis confirmed by ultrasound or low-dose CT; stone long diameter ≤ 20 mm (for upper ureteral stones, diameter ≤ 15 mm); absence of urinary tract structural malformations.\n* Meeting the indications for ESWL with no absolute contraindications, and scheduled to undergo ESWL treatment.\n* Guardians provide informed consent and voluntarily sign the written informed consent form; willing and able to cooperate with the 4-week postoperative follow-up and related examinations.\n* Preoperative assessment reveals no contraindications to ESWL, such as uncontrolled infection, severe coagulation disorders, or severe impairment of cardiopulmonary, hepatic, or renal function.\n\nExclusion Criteria:\n\n* Presence of absolute contraindications for ESWL: Uncontrolled severe urinary tract infection or sepsis; severe uncorrected coagulopathy or current use of anticoagulant\u002Fantiplatelet medications; severe renal impairment (significantly decreased GFR); active severe cardiopulmonary disease rendering the patient unable to tolerate anesthesia or shock wave therapy; or absence of an anatomically safe shock wave path (e.g., due to severe skeletal deformities).\n* Stones suspected to be extremely hard or complex: Refractory stones indicated by excessively high CT Hounsfield Units (HU) or ultrasound Shear Wave Elastography (SWE) values \\> 13.7 kPa; or cystine stones in children \\> 2 years of age (associated with significantly low ESWL success rates).\n* Anatomical or physiological challenges: Severe obesity that compromises ultrasound localization; or patients with a solitary kidney or poor contralateral renal function accompanied by a large stone burden.\n* Prior intervention: History of prior ESWL or other lithotripsy procedures at the target site, which may confound the evaluation of therapeutic efficacy.\n* Underlying systemic conditions: Comorbid severe metabolic diseases or hereditary stone diseases (e.g., cystinuria) requiring priority comprehensive management.\n* Compliance issues: Guardians unable to cooperate with the complete follow-up process, or patients with a high anticipated risk of being lost to follow-up.","1 Year","14 Years",{"count":304,"type":22},80,[25],"The incidence of pediatric urinary system stones has shown an upward trend in recent years, and Extracorporeal Shock Wave Lithotripsy (ESWL) has become one of the most important minimally invasive treatments for pediatric upper urinary tract stones. Currently, the widely used clinical ultrasound mechanical coupling localization mode suffers from issues such as limited scanning degrees of freedom and difficulty in intuitively grasping the spatial relationship between the stone and the focal point. These issues lead to prolonged stone pre-localization times, significant reliance on operator experience, and a steep learning curve for young and primary care physicians, thereby restricting the standardization and widespread promotion of pediatric ESWL.\n\nBuilding upon existing ESWL equipment, this project independently constructs an \"Optical Motion Capture-Assisted Ultrasound Pre-localization System.\" By utilizing multi-camera infrared motion capture to acquire the 3D pose of the ultrasound probe and the shock wave source in real-time and establishing a unified spatial coordinate system, the system achieves automatic conversion and visual display of the stone's position from the ultrasound image to the shock wave focal point coordinates. This guides the operator to quickly complete focal point pre-localization after freely scanning for the stone. Results from preliminary phantom studies and initial clinical pilot experiments indicate that, while maintaining the routine ESWL workflow, this system can significantly shorten the first effective pre-localization time for pediatric stones from approximately 15 minutes to around 5 minutes, without a significant decrease in the stone clearance rate. This suggests the technology possesses good engineering feasibility and clinical application prospects.\n\nThis study proposes to conduct a single-center, prospective, single-blind randomized controlled clinical trial. Pediatric patients with upper urinary tract stones eligible for ESWL will be randomly assigned 1:1 to an experimental group and a control group. The experimental group will use the Optical Motion Capture-Assisted Ultrasound Pre-localization System for stone pre-localization, while the control group will use the routine ultrasound mechanical coupling localization method.\n\nThe \\*\\*primary outcome measure\\*\\* is the time to first effective stone pre-localization. \\*\\*Secondary outcomes\\*\\* include the stone clearance rate evaluated by imaging at 4 and 12 weeks post-operation, the total number of shock waves released and total energy, total procedure time, intraoperative and postoperative complication rates, sedation\u002Fanesthesia dosage, and family satisfaction. Additionally, the study will systematically evaluate the system's impact on physician learning curves and work intensity by analyzing the localization success rate of operators with different seniority levels, learning curves (the trend of localization time versus the number of cases), and subjective workload scores.\n\nThe core scientific question this project aims to answer is: Under the premise of not compromising the therapeutic efficacy and safety of pediatric ESWL, can optical motion capture-assisted ultrasound pre-localization significantly improve stone localization efficiency, reduce operator workload, and shorten the learning curve for young physicians, thereby enhancing the standardization and accessibility of pediatric ESWL? The expected results will provide an evidence-based foundation for optimizing pediatric ESWL localization modes and formulating relevant technical standards and training programs. Furthermore, it will lay the clinical validation groundwork for future intelligent lithotripsy systems integrating functions such as intelligent identification and robotic arm automatic tracking.",[308,309,310,311,31,312],"Pediatric Urolithiasis","Extracorporeal Shock Wave Lithotripsy","Optical Motion Capture","Ultrasound Localization","Localization Efficiency","2026-01-05",{"date":315,"type":37},"2026-01-06",{"date":317,"type":22},"2026-01-01",{"date":319,"type":22},"2028-01-01",{"name":321,"class":44},"The Children's Hospital of Zhejiang University School of Medicine",{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100606149","comparing-3d-and-2d-views-in-biportal-spine-surgery-a-pilot-simulation-study-100606149","NCT07171801","Comparing 3D and 2D Views in Biportal Spine Surgery: A Pilot Simulation Study","3D vs. 2D Unilateral Biportal Endoscopic Spine Surgery: A Randomized Blinded Crossover Pilot Simulation Study","Inclusion Criteria:\n\n* Enrolled in the neurosurgical residency or fellowship program at the Department of Neurosurgery, Cantonal Hospital of St. Gallen, Switzerland\n* Completion of basic neurosurgical training modules, including introductory endoscopic handling\n* Age ≥ 18 years\n* Willingness and ability to provide informed consent\n\nExclusion Criteria:\n\n* Prior substantial experience with three-dimensional (3D) endoscopy (defined as \\> 5 independent procedures performed with 3D visualization systems)\n* Ocular or neurological conditions impairing stereopsis, fine motor control, or safe endoscope handling\n* Inability or unwillingness to complete the simulation protocol\n* Declined participation",{"count":330,"type":22},6,[25],"This study aims to compare three-dimensional (3D) and two-dimensional (2D) visualization in biportal endoscopic spine surgery using a simulated environment. Surgeons will perform standardized tasks on a spine model while using either 3D or 2D endoscopic systems. The goal is to determine whether 3D technology can improve precision, efficiency, and movement control during surgery. The study uses a randomized, blinded, crossover design to ensure objective results and may help guide future training and technology use in spinal endoscopy.",[334,335,336,31,337,338],"Spinal Diseases","Endoscopy Simulation","Lumbar Vertebrae","Three-Dimensional","Simulation Training","2025-09-15",{"date":341,"type":37},"2025-09-16",{"date":343,"type":22},"2025-10-01",{"date":345,"type":22},"2025-12-01",{"name":347,"class":44},"Felix Corr",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":359,"conditions":360,"keywords":365,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":45},"100603996","phase-4-sglt2i-safety-and-efficacy-on-kidney-allograft-function-in-non-diabetic-kidney-transplant-recipients-100603996","NCT07143773","SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients","SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Double-blind, Placebo Controlled, National, Multicenter Trial","SGL-TX-GFR","Inclusion Criteria:\n\n* Obtained written informed consent\n* Male or female patients, age ≥ 18 years.\n* Non-diabetic KTR\n* \\> 6 months post-transplant\n* eGFR\\> 25 ml\u002Fmin\u002F1.73m2 within the last 3 months pre randomization\n* Immunosuppressive must include Tacrolimus\n* Negative plasma hCG in fertile women\\*, and acceptance of the use of contraception during the course of the study.\n\nExclusion Criteria:\n\n* Patients treated (diet or antidiabetics) for diabetes type 1 or 2 before randomization\n* eGFR\\\u003C 25 ml\u002Fmin\u002F1.73m2 (before randomization)\n* Alanine aminotransferase (ALAT) \\> 3 x upper normal limit\n* Bilirubin \\> 2 x upper normal limit\n* Pregnancy\n* Breastfeeding\n* Known allergy towards SGLT2i or the content substance\n* Known intestinal bowel disease",{"count":255,"type":22},[358],"PHASE4","This clinical trial investigates whether 18 months of daily SGLT2i (10 mg Forxiga) preserves kidney function and evaluates safety, based on eGFR changes and adverse event occurrence in non-diabetic kidney transplant recipients.\n\nThe main questions it aims to answer are:\n\n* Does SGLT2i versus placebo, as an add-on to standard care, preserve kidney transplant function in non-diabetic recipients?\n* Is SGLT2i treatment safe for non-diabetic transplant recipients when evaluating adverse events?\n* Does SGLT2i versus placebo affect the occurrence of urinary tract infections, post-transplant diabetes mellitus (PTDM) and prediabetes incidence, U-ACR, as well as renal and cardiovascular parameters?\n\nResearchers will compare a daily dose of SGLT2i (10 mg Forxiga) with a placebo (a look-alike tablet with no active medicine).\n\nKidney transplant recipients who do not have diabetes can take part if they meet the study's requirements. Participants will be randomly assigned to receive either Forxiga or placebo once daily for 18 months. All participants will have check-ups every 3 months, which will include urine tests and blood samples. Neither the participants nor the study doctors will know which treatment they are receiving.",[361,362,363,31,364],"Kidney Transplantation Recipients","Sodium-Glucose Transporter 2 Inhibitors","Non-Diabetic Patients","Placebo Control Design",[366,367,368,369,370,371],"SGLT2i","Kidney Transplant","Kidney Transplant Recipients","non-diabetic patients","Sodium-glucose Transporter 2 inhibitors","RCT","2025-08-22",{"date":374,"type":37},"2025-08-27",{"date":376,"type":22},"2025-09-01",{"date":378,"type":22},"2027-08-01",{"name":380,"class":44},"Odense University Hospital",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":200,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":45},"100601522","personalized-health-coaching-for-patients-with-hf-100601522","NCT07111585","Personalized Health Coaching for Patients With HF","Effect of Personalized Health Coaching Program in Patients With Frailty and Heart Failure","Coach-FrailHF","Inclusion Criteria:\n\n* Participants aged 40 years or older will be included in the study, as heart failure (HF)-related mortality and the prevalence of HF increase significantly from this age onward. Inclusion criteria requires a diagnosis of acute HF by a cardiologist and hospitalization based on the following criteria: presence of HF symptoms (e.g., breathlessness, fatigue, ankle swelling) and signs (e.g., elevated jugular venous pressure, pulmonary crackles, peripheral edema), evidence of pulmonary congestion or edema on chest X-ray, and elevated levels of BNP (≥100 pg\u002FmL) or NT-proBNP (≥300 pg\u002FmL). After initial screening for frailty using both the Tilburg Frailty Indicator (TFI) and Fried's Phenotype (FP), participants will be enrolled if they are classified as frail, able to cooperate with functional assessments, and willing to provide written informed consent with a clear understanding of the study's purpose and procedures.\n\nExclusion Criteria:\n\n* The exclusion criteria were as follows: current enrollment in other programs or planning to participate in similar programs during the intervention period; residing outside Korea and not understanding Korean; diagnosis of dementia with the Global Deterioration Scale stage of 5 or greater; inability to comprehend the study purpose and content.",{"count":304,"type":22},[25],"Frailty in heart failure (HF) patients contributes to poor outcomes, emphasizing the need for effective management. In many previous studies, frailty interventions have mainly targeted physical frailty or focused community-dwelling patients, neglecting the multidimensional needs of hospitalized individuals. As a frailty for HF patients need to include clinical, functional, cognitive, and social domains, nurses must assess it holistically and provide personalized support, especially during care transitions. This study aims to evaluate the effectiveness of a nurse-led, personalized health coaching program for hospitalized HF patients with frailty through a randomized controlled trial. This 12-week intervention program targets hospitalized HF patients with frailty. After screening frailty HF patients using validated tools such as Fried's phenotype (FP), Tilburg Frailty Indicator (TFI), participants will be randomly assigned to either an intervention or control group. The intervention group will receive personalized health services, including pre-discharge education and weekly telephone coaching, addressing clinical, functional, psycho-cognitive, and social frailty domains. Psychiatric support and community integration program will be provided as needed. The control group will receive standard care. Frailty, QoL, and clinical outcomes will be measured at baseline, 12 weeks, and 24 weeks. The primary outcomes will be improvements in frailty and QoL. Frailty will be measured both multidimensional and each of the four domains of frailty for HF patients. This study will clarify the role of multidimensional personalized interventions in addressing adverse outcomes related to frailty in patients with HF, thereby providing evidence of their necessity in its management.",[393,394,395,396,397,31],"Heart Failure","Frailty","Health Coaching","Telenursing","Patient Monitoring","2025-08-07",{"date":400,"type":37},"2025-08-08",{"date":402,"type":37},"2025-07-03",{"date":404,"type":22},"2027-06",{"name":406,"class":44},"Gachon University Gil Medical Center",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":54,"sex":17,"minAge":200,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":45},"100592065","the-impact-of-ai-assistance-on-radiologist-performance-and-healthcare-costs-in-ldct-based-lung-cancer-screening-100592065","NCT06988579","The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening","Evaluation of AI-Assisted Versus Conventional Human Reading for Lung Cancer Screening in Community-Based Settings: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 45-74 years\n2. Permanent resident of participating study communities\n3. No prior history of lung cancer and no lung cancer screening within the past 3 months\n4. Able to comprehend and voluntarily sign informed consent, with willingness to participate in long-term follow-up\n\nExclusion Criteria:\n\n1. Individuals with a confirmed diagnosis of lung cancer\n2. Those with severe comorbidities contraindicating CT imaging\n3. Inability to understand study protocols or provide informed consent due to cognitive impairment\n4. Concurrent participation in other clinical trials that may interfere with study outcomes\n5. Unable to comply with follow-up requirements","74 Years",{"count":416,"type":22},7294,[25],"AI diagnostic systems show great promise for improving lung cancer screening in community healthcare settings. While not originally designed for primary care, these tools demonstrate capabilities in nodule detection and workflow optimization. However, their effectiveness in resource-limited community centers requires thorough evaluation.\n\nThis RCT compares AI-assisted versus manual CT interpretation across community health centers. Expert radiologists will establish reference standards, while an independent committee blindly evaluates cases from both groups. The study assesses diagnostic accuracy, operational efficiency, and cost-effectiveness, with blinded analysts resolving discrepancies through consensus to ensure reliable results.",[420,421,31],"Lung Cancer","Artificial Intelligence (AI)","2025-06-23",{"date":424,"type":37},"2025-06-26",{"date":426,"type":37},"2024-07-01",{"date":428,"type":22},"2026-01-07",{"name":430,"class":44},"The First Affiliated Hospital of Guangzhou Medical University",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":200,"maxAge":19,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":448,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":458},"100570936","remote-ischemic-conditioning-for-non-proliferative-diabetic-retinopathy-100570936","NCT06713720","Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy","Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy (RIC-NPDR)","RIC-NPDR","Inclusion Criteria:\n\n* Age between 40 and 80 years.\n* Diagnosed with Type 2 diabetes mellitus.\n* Diagnosed with mild to moderate non-proliferative diabetic retinopathy (NPDR) with a DR Severity Score (DRSS) grade of 20-47D.\n* Capable of performing daily activities independently.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Presence of diabetic macular edema (macular thickness \\> 250 μm).\n* Significant eye diseases affecting evaluation, such as high myopia, severe cataract, corneal leucoma, glaucoma, retinal detachment, retinal vein occlusion, congenital eye diseases, ocular tumors, or severe infection.\n* History of ocular laser or intraocular surgery.\n* Poor imaging quality due to refractive media opacity.\n* Contraindication to fluorescein fundus angiography.\n* Unstable blood glucose (HbA1c ≥ 8.0%) despite oral antidiabetic drugs.\n* Severe diabetes complications within the past 6 months.\n* Severe, sustained hypertension (systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg).\n* Body mass index (BMI) ≥ 28 kg\u002Fm².\n* Hepatic or renal insufficiency: Alanine aminotransferase or aspartate aminotransferase \\> 2 times the upper limit of normal. Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73m². Urine albumin\u002Fcreatinine ratio ≥ 30 mg\u002Fg.\n* Myocardial infarction within the past 6 months.\n* Neurological diseases such as Alzheimer's, Parkinson's, cerebrovascular disease, intracranial tumor, cerebrovascular malformation, or aneurysm.\n* Contraindications to RIC, including one-sided subclavian artery stenosis, upper limb injuries or vascular diseases, or limb deformities.\n* Severe systemic diseases, such as malignant tumors with a life expectancy of less than 24 months.\n* Known pregnancy or breastfeeding.\n* Participation in other experimental clinical studies.\n* Any other conditions deemed unsuitable by the investigator.",{"count":440,"type":22},68,[25],"The goal of this clinical trial is to evaluate whether remote ischemic conditioning (RIC) is a safe and effective treatment for non-proliferative diabetic retinopathy (NPDR) in adults aged 40-80 years with type 2 diabetes. The study aims to address the limitations of current treatments for NPDR by using RIC, a technique involving repeated cycles of ischemia and hypoxia stimulation to activate protective mechanisms against retinal damage.\n\nThe main questions it aims to answer are:\n\nDoes RIC improve the Diabetic Retinopathy Severity Score (DRSS) after one year of treatment? Does RIC reduce the incidence of vision-threatening proliferative diabetic retinopathy (PDR)? What are the changes in retinal neurovascular unit parameters, visual acuity, and retinal oxygen saturation after RIC treatment?\n\nParticipants will:\n\nUndergo RIC therapy using a specialized device on both upper limbs (or a placebo intervention for the control group) for 1 year.\n\nComplete 5 cycles of RIC or placebo treatment twice daily, 5 days per week. Receive routine care for diabetic retinopathy as per clinical guidelines.\n\nKey outcome measures:\n\nPrimary outcome: Change in DRSS from baseline after one year. Secondary outcomes: Incidence of PDR, changes in visual acuity, retinal neurovascular unit measures, retinal oxygen saturation, and serum biomarkers (e.g., VEGF, CRP, IL-6).\n\nThis randomized, double-blind, placebo-controlled trial aims to recruit 68 participants to ensure 60 complete the study, accounting for a 13% dropout rate. The findings are expected to provide insights into RIC as a novel intervention for NPDR, reducing blindness risk and supporting future large-scale trials.",[444,445,446,447,31],"Diabetic Retinopathy","Non-Proliferative Diabetic Retinopathy","Remote Ischemic Conditioning","Diabetes Mellitus, Type 2",[445,444,449,446,31],"Retinal Neurovascular Unit","2025-06-22",{"date":424,"type":37},{"date":453,"type":37},"2025-04-20",{"date":455,"type":22},"2026-05-31",{"name":457,"class":44},"Xuxiang Zhang, MD",2,{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":467,"enrollmentInfo":468,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":475,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":488},"100593757","comparison-of-ultrasound-abbreviated-mri-with-and-without-hbp-as-modalities-for-hcc-surveillance-in-patients-with-high-risk-100593757","NCT07010588","Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk","Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk: a Multi-centers, Randomized Controlled Open-label Trial","SHORT","Inclusion criteria\n\n* According to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) from department of medical administration, nation health commission of the People's Republic of China, with any one of the following high-risk factors for liver cancer: hepatitis B and\u002For C virus infection, excessive alcohol consumption, hepatic steatosis or metabolic dysfunction-associated liver disease, dietary exposure to aflatoxin B1, liver cirrhosis from other causes, or a family history of liver cancer, and an aMAP score (age⁃male⁃albi⁃platelets score) of 60-100 points.\n* Liver disease patients with no evidence of suspected liver cancer in any imaging examination (liver US, contrast-enhanced CT, or contrast-enhanced MRI) within the past six months.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of previous liver cancer diagnosis.\n* Baseline screening at enrollment diagnosed with liver cancer.\n* Child-Pugh score ≥ 10 (class C).\n* History of other malignant tumors.\n* Pregnant or lactating women.\n* Clinically diagnosed severe heart\u002Flung disease or uncontrolled comorbidities, with investigator-judged life expectancy \\\u003C 2 years.\n* Glomerular filtration rate \\\u003C 50 mL\u002Fmin.\n* Inability to undergo (enhanced) MRI due to contraindications or relative contraindications.\n* Poor compliance or unsuitability for the clinical trial as judged by the investigator.","75 Years",{"count":469,"type":22},1389,[25],"Active surveillance in high-risk hepatocellular carcinoma (HCC) populations enables early detection of tumors. The currently recommended monitoring protocol involves biannual serum alpha-fetoprotein (AFP) testing combined with liver ultrasound (US) examinations. However, conventional US demonstrates limited sensitivity in detecting early-stage HCC lesions.\n\nMRI demonstrates high sensitivity in monitoring cirrhotic patients, but prolonged scanning time limits its routine clinical application. Several abbreviated MRI protocols have been developed for HCC detection, aiming to reduce acquisition time while improving early-stage HCC diagnostic accuracy.\n\nThe main question this clinical trial aims to answer is:\n\nCan non-contrast abbreviated MRI (NC-AMRI) and enhanced abbreviated MRI (E-AMRI) detect more early-stage HCC lesions compared to US-based screening? Researchers will randomly divide the participants into three groups in a 1:1:1 ratio, with different surveillance strategies, focused on early HCC detection rates.",[473,474,31],"Hepatocellular Carcinoma (HCC)","Magnetic Resonance Imaging (MRI)",[476,477,478],"Hepatocellular carcinoma","magnetic resonance imaging","surveillance","2025-05-29",{"date":481,"type":37},"2025-06-08",{"date":483,"type":22},"2025-06",{"date":485,"type":22},"2030-06",{"name":487,"class":44},"Peking University People's Hospital",12,{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":55,"minAge":496,"maxAge":126,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":499,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":45},"100592227","phase-2-effect-of-salidroside-on-pregnancy-outcomes-in-high-childbearing-age-patients-in-viro-fertilization-100592227","NCT06990685","Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization","Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization: an Open-label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥35 and \\\u003C 40 years old\n2. For the first or second cycle of IVF, ICSI or IVF with donor sperm\n3. According to the 2016 Poseton criteria for poor prognosis: the number of oocytes obtained in the previous routine ovulation induction protocol was 1-9, or AFC \\\u003C 5 or AMH \\\u003C 1.2ng\u002Fml (measured within the past half year) in both ovaries.\n\nExclusion Criteria:\n\n1. Patients with coagulation disorders\n2. Patients with previous abnormal uterine bleeding\n3. Combined with hydrosalpinx confirmed by B-ultrasound and HSG\n4. Uterine malformation (unicornuate uterus, septate uterus) or history of intrauterine adhesions\n5. Patients with previous spontaneous abortion ≥3 times\n6. Patients with contraindications to assisted reproductive technology or pregnancy\n7. Previous or current oral medication containing salidroside\n8. The controlled ovarian stimulation protocol included PPOS protocol, luteal phase ovulation induction protocol, and continuous stimulation protocol","35 Years",{"count":498,"type":22},370,[500],"PHASE2","With the decreasing of birth rate and population in our country, population problem has become a long-term and strategic problem. In addition to the decrease in the number of women of childbearing age and the impact of unmarried women, the increase in the incidence of reproductive disorders and the delay of marriage and childbearing are also important factors leading to the continuous decline of the birth population in China. Among them, ovarian aging is a key factor causing female fertility difficulties. Therefore, establishing an effective prevention and treatment strategy for ovarian aging is of great significance for improving female reproductive health and serving the national population strategy. Recently, several supplements have been found to promote folliculogenesis and improve oocyte quality. However, to date, there is no approved therapeutic agent for the treatment of ovarian aging. Therefore, it is urgent to develop effective strategies for the prevention and treatment of ovarian aging.\n\nSalidroside is the main active component of Chinese medicine Rhodiola, and its content is highest in the root of rhodiola, which is also the main medicinal part. The main efficacy of salidroside in traditional Chinese medicine is to benefit qi, promote blood circulation, unblock pulse and relieve asthma. At the same time, in basic research, more and more experiments have shown that salidroside has a variety of pharmacological properties, including anti-hypoxia, anti-fatigue and anti-aging effects, anti-cancer, anti-inflammatory, anti-oxidation, antiviral and so on. These pharmacological effects suggest that salidroside may be an effective drug for the prevention and treatment of atherosclerosis, Parkinson's disease, Alzheimer's disease, pneumonia and other diseases. In terms of aging, it has been confirmed that salidroside supplementation can prolong the life span of pseudogill oryzias zhan and rescue premature aging of human skin fibroblasts, etc., which further confirms.\n\nThe aim of this study is to investigate the efficacy of salidroside as an adjuvant drug in improving the pregnancy outcomes of fresh embryo transfer in high childbearing age patients with poor ovarian response by comparing the pregnancy outcomes of fresh embryo transfer between salidroside group and blank control group. This pragmatic clinical study is expected to improve pregnancy outcomes of fresh embryo transfer cycles in women of advanced childbearing age with poor ovarian response.",[503,31,504,505],"Salidroside","In Vitro Fertilization","Assisted Reproductive Technology","2025-05-22",{"date":508,"type":37},"2025-05-25",{"date":510,"type":22},"2025-06-01",{"date":512,"type":22},"2027-12",{"name":514,"class":44},"The Second Hospital of Shandong University",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":525,"briefSummary":526,"conditions":527,"keywords":530,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":4},"100591654","exploring-nursing-students-ability-to-create-artificial-intelligence-enhanced-patient-education-materials-on-infection-care-100591654","NCT06983236","Exploring Nursing Students' Ability to Create Artificial Intelligence-Enhanced Patient Education Materials on Infection Care","Exploring Nursing Students' Ability to Create Artificial Intelligence-Enhanced Patient Education Materials on Infection Care: A Randomized Controlled Trial","Inclusion Criteria:\n\n* To take Basic Principles and Practices in Nursing-II for the first time\n* Not to work as a nurse in a hospital or any health institution\n\nExclusion Criteria:\n\n* Having previously prepared patient education materials;\n* Retaking the Basic Principles and Practices in Nursing-II course\n* Having difficulty speaking and understanding Turkish;\n* Not attending class","38 Years",{"count":524,"type":22},110,[25],"The purpose of this study is to explore the ability of nursing students to create artificial intelligence-supported patient education materials regarding infection care. This study will be conducted as a randomized controlled experimental study. Data of the study will be collected with the Descriptive Characteristics Form, Patient Education Information Form and Patient Education Materials Assessment Tool (HEMDA).",[528,421,529,31],"Nursing Students","Patient Education Materials",[528,421,529,531],"Randomized controlled trial","2025-05-13",{"date":534,"type":37},"2025-05-21",{"date":536,"type":22},"2025-05-16",{"date":538,"type":22},"2025-06-25",{"name":540,"class":44},"Çankırı Karatekin University",{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":55,"minAge":18,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":23,"phases":550,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":561,"locationsCount":45},"100584165","uterine-round-ligament-preservation-vs-resection-in-laparoscopic-inguinal-hernia-repair-in-womena-multicenterstratified-randomized-controlled-trial-100584165","NCT06885788","Uterine Round Ligament Preservation Vs Resection in Laparoscopic Inguinal Hernia Repair in Women：A Multicenter,Stratified Randomized Controlled Trial","Comparative Study on the Effect of Uterine Round Ligament Preservation Vs Resection in Laparoscopic Inguinal Hernia Repair in Women： a Multicenter,Stratified Randomized Controlled Trial","Inclusion Criteria:\n\n* ►Age : Female patients over 18 years of age without a childbearing requirement\n\n  * Diagnosis and basis : Female patients diagnosed with Unilateral inguinal hernia.\n  * agreed to participate in this study and signed the informed consent form.\n\nExclusion Criteria:\n\n* ►Combined with severe heart, liver, kidney and other diseases.\n\n  * pregnant or lactating women.\n  * those with surgical contraindications.",{"count":549,"type":22},466,[25],"This study aims to compare the clinical effects of uterine round ligament preservation versus resection in laparoscopic inguinal hernia repair in women.The primary outcomes included Time required for patient surgery.The secondary outcomes included Inguinal hernia recurrence,quality of life assessment,Indicators of postoperative recovery,, et al.",[553,554,31],"Inguinal Hernia","Laparoscopic Surgery","2025-03-20",{"date":557,"type":37},"2025-03-25",{"date":559,"type":37},"2024-09-20",{"date":245,"type":22},{"name":562,"class":164},"Nanchong Central Hospital",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":587,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":330},"100523911","coronary-computed-tomography-versus-invasive-angiography-for-non-st-elevation-acute-coronary-syndrome-100523911","NCT06101862","Coronary Computed Tomography Versus Invasive Angiography for Non-ST Elevation Acute Coronary Syndrome","Team-based Interventional Triage in Acute Coronary Syndrome Based on Non-Invasive Computed Tomography Coronary Angiography - a Randomized Trial","TRACTION","Inclusion criteria:\n\n* Admitted with non-ST-segment elevation myocardial infarction or unstable angina pectoris and an indication for subacute ICA\n* Elevated troponin or ischemic electrocardiographic changes\n* Written informed consent\n\nExclusion criteria:\n\n* Instability requiring acute or emergent ICA\n* History of percutaneous coronary intervention or coronary artery bypass grafting\n* Estimated glomerular filtration rate \\< 30 mL\u002Fmin\u002F1.73m2\n* Probable type 2 acute myocardial infarction\n* Severe valvular heart disease as primary diagnosis or potential need for valve intervention\n* History of spontaneous coronary artery dissection\n* Expected poor quality of the CCTA\n* Prior CCTA or ICA during index admission or within 1 week\n* Known allergy to beta-blockers or contrast agent\n* Pregnant or nursing\n* Previously randomized in this trial",{"count":572,"type":22},2300,[25],"Coronary computed tomography angiography (CCTA) is a widely accepted initial diagnostic test for individuals suspected of having chronic coronary syndromes. However, there is limited evidence supporting its use in the acute setting. So far, no large-scale randomized trial has examined the performance of CCTA as an alternative to invasive coronary angiography (ICA) in individuals with non-ST-segment elevation myocardial infarction (NSTEACS).\n\nIf CCTA were to replace ICA as a routine procedure for individuals with NSTEACS, it could reduce the risk of complications related to ICA, improve patient comfort, expedite decision-making, and reduce healthcare expenses and interhospital transfers.",[576,577,578,579,580,581,31,582,583,584,585,586],"Ischemic Heart Disease","Non STEMI","Angina Pectoris, Unstable","Coronary Disease","Heart Attack","Acute Myocardial Infarction (AMI)","Diagnostic Imaging","Coronary Stenoses","Coronary Artery Disease","Multidetector Computed Tomography","Percutaneous Coronary Intervention",[588,589,590,591,592,593,594,595,569,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613],"Angiography","Computed Tomography","Coronary","Non-STEACS","CCTA","ICA","Randomized","Interventional Triage","Diagnostic imaging","Interventional cardiology","VERDICT","CT","Coronary Angiography","Complications","Coronary CT-team","Ischemic heart disease","Acute myocardial infarction","Non-ST-elevation myocardial infarction (NSTEMI)","Unstable angina pectoris","Percutaneous coronary intervention","Coronary artery bypass grafting","PCI","CABG","Diagnostic procedure","Interhospital transfers","Myocardial Ischemia","2025-02-14",{"date":616,"type":37},"2025-02-19",{"date":618,"type":37},"2023-10-01",{"date":620,"type":22},"2036-10-01",{"name":622,"class":44},"Rigshospitalet, Denmark",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":631,"targetDuration":4,"studyType":23,"phases":633,"briefSummary":634,"conditions":635,"keywords":642,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":45},"100508571","electronic-patient-decision-support-system-for-patients-with-type-2-diabetes-diapadess-100508571","NCT05902156","Electronic Patient Decision Support System for Patients with Type 2 Diabetes (DiaPaDeSS)","The Effect of Electronic Patient Decision Support System Developed for Use Patients with Type 2 Diabetes (DiaPaDeSS) on Self-Management, Patient Activation and Metabolic Parameters","DiaPaDeSS","Inclusion Criteria:\n\n* Patients with type 2 diabetes who had been followed up and treated at the Endocrinology and Metabolic Diseases Polyclinic\n* Aged between 18-65 years\n* Patients who know their diagnosis and can verbally express it\n* Have been diagnosed with type 2 diabetes for at least six months\n* Who are literate\n* Who have internet access at home, who have one of the tools such as a computer, tablet or smartphone and can use these tools\n* Consented to participate in the study\n* Had no other psychiatric or mental barriers to answering the questions, language or cognitive difficulties, and barriers to verbal or written communication\n\nExclusion Criteria:\n\n* Diagnosed with myocardial infarction, stroke or diabetic foot in the last six months\n* Diagnosed with type 1 diabetes or gestational diabetes\n* Diagnosed with terminal illness\n* Using steroid therapy\n* Had pregnant\n* Having dementia and cognitive deficits\n* Having retinopathy or advanced neuropathy\n* Patients whose information is not allowed to be accessed",{"count":632,"type":22},72,[25],"This study evaluates the effects of an electronic patient decision support system developed for the use of patients with type 2 diabetes (DiaPaDeSS) on self-management, patient activation, and metabolic parameters. To manage type 2 diabetes after discharge, patients must continue to perform interventions at home, such as blood glucose monitoring, blood pressure measurement, weight measurement, medication use, and foot care. To achieve this, patient's self-management and activation levels should be increased. This can also lead to positive improvements in the metabolic parameters. It would be beneficial to develop DiaPaDeSS that can increase the self-management and activation levels of patients with type 2 diabetes. The investigators will develop the DiaPaDeSS intervention protocol. Our content includes patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), a type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires. The content of the DiaPaDeSS will be evaluated by 10 experts in the fields of medicine, nursing, and informatics. A feasibility test with seven patients will be conducted to evaluate the usability of DiaPaDeSS. A single-blind, randomized controlled trial design will be used. Patients with type 2 diabetes will be pretested and randomized (intervention 36, control 36) to the DiaPaDeSS intervention and control groups. Both the DiaPaDeSS intervention and control groups will use the DiaPaDeSS for three months. While participants in the DiaPaDeSS intervention group can reach all contents of the DiaPaDeSS, others can reach only these fields: self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The effectiveness of the DiaPaDeSS will be evaluated at baseline and at month 3.",[636,637,638,639,640,641,31],"Mobile Health","Type 2 Diabetes","Patient Activation","Self-Management","Decision Support System","Nursing",[636,637,638,640,639,641,31],"2025-02-04",{"date":645,"type":37},"2025-02-06",{"date":647,"type":22},"2025-03-30",{"date":649,"type":22},"2025-11-01",{"name":651,"class":44},"Akdeniz University",{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":54,"sex":17,"minAge":659,"maxAge":4,"enrollmentInfo":660,"targetDuration":4,"studyType":23,"phases":662,"briefSummary":663,"conditions":664,"keywords":667,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":45},"100520595","effects-of-a-computerised-cognitive-stimulation-versus-stimulating-leisure-activities-100520595","NCT06058611","Effects of a Computerised Cognitive Stimulation Versus Stimulating Leisure Activities","Effects of a Personalised and Tailored Computerised Cognitive Stimulation Programme Versus Stimulating Leisure Activities in Older Adults with Mild Cognitive Impairment and Subjective Cognitive Impairment: Randomised Controlled Trial","Inclusion Criteria:\n\n* ≥ 50 years old, resident in the community.\n* Diagnosis of MCI or having between 24 and 27 points on the MEC-35 (this score seems to indicate the presence of MCI) (Calero, M. D and Navarro, 2006).\n* Subjective cognitive impairment (score between 28-31 points on the MEC-35) (Gómez-Soria et al. 2023)\n\nExclusion Criteria:\n\n* Institutionalisation.\n* Taking acetylcholinesterase inhibitors as they may act on global cognition and\u002For cognitive functions.\n* Sensory deficits (deafness and blindness) preventing intervention.\n* Agitation.\n* Having received cognitive stimulation in the last 12 months.","50 Years",{"count":661,"type":22},90,[25],"The aim of the study is to evaluate, at the level of global cognition, cognitive neuroconstructs, memory, verbal fluency, ADLs, IADLs, symptoms of depression and anxiety, the effectiveness of a personalised and adapted computerised cognitive stimulation programme (GI1) implemented from Primary Care versus stimulating leisure activities (GI2), in older adults aged 50 years and over with mild cognitive impairment and subjective cognitive impairment living in the community.",[665,31,666],"Mild Cognitive Impairment","Subjective Cognitive Impairment",[665,668,669,31,670,671,672,673,666],"Older adults","Elderly","Cognitive Stimulation","Cognitive Intervention","Cognitively Stimulating Leisure Activities","Leisure Activities","2024-12-06",{"date":676,"type":37},"2024-12-12",{"date":678,"type":37},"2024-04-01",{"date":680,"type":22},"2025-09-30",{"name":682,"class":44},"Universidad de Zaragoza",{"id":684,"slug":685,"hasResults":12,"nctId":686,"briefTitle":687,"officialTitle":688,"acronym":4,"eligibilityCriteria":689,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":690,"targetDuration":4,"studyType":23,"phases":692,"briefSummary":693,"conditions":694,"keywords":695,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":701,"completionDateStruct":703,"leadSponsor":705,"locationsCount":45},"100562639","enhancing-psychiatric-nursing-skills-in-auditory-hallucination-assessment-via-arvr-and-virtual-osce-100562639","NCT06605781","Enhancing Psychiatric Nursing Skills in Auditory Hallucination Assessment Via AR\u002FVR and Virtual OSCE","Enhancing Auditory Hallucination Assessment and Intervention Skills of Psychiatric Nursing Student Through AR\u002FVR Technology and OSCE in Virtual Clinical Environments","Inclusion Criteria:\n\n* Nursing students who are about to undertake their psychiatry practicum.\n* Those who are willing to join the study and sign the consent form.\n* Those who are willing to bring a smartphone to connect with VR360 and watch the video.\n* Those who are willing to use their smartphone for research purposes (a smartphone will be provided by the research team if needed).\n\nExclusion Criteria:\n\n* Individuals with hearing or vision impairments",{"count":691,"type":22},150,[25],"The purpose of this study is to develop and evaluate AI-based virtual reality teaching resources aimed at enhancing nursing students' competencies in assessing, communicating with, and managing patients experiencing auditory hallucinations. Specifically, this study seeks to improve the ability of nursing students to effectively assess auditory hallucinations, facilitate better communication with patients experiencing such disturbances, and strengthen their skills in managing these symptoms through the implementation of virtual reality-based educational scenarios.",[31],[696,697,698],"duditory hallucination assessment","nurse student","AR\u002FVR","2024-09-18",{"date":559,"type":37},{"date":702,"type":22},"2024-09-10",{"date":704,"type":22},"2025-07",{"name":706,"class":44},"National Yang Ming Chiao Tung University",{"id":708,"slug":709,"hasResults":12,"nctId":710,"briefTitle":711,"officialTitle":712,"acronym":4,"eligibilityCriteria":713,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":714,"targetDuration":4,"studyType":23,"phases":716,"briefSummary":717,"conditions":718,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":726,"completionDateStruct":728,"leadSponsor":730,"locationsCount":330},"100543611","buyuan-zhixiao-formula-in-the-treatment-of-elderly-patients-with-diabetes-and-multiple-metabolic-disorders-100543611","NCT06358118","Buyuan-zhixiao Formula in the Treatment of Elderly Patients With Diabetes and Multiple Metabolic Disorders","Clinical Research on Evidence Based Traditional Chinese Medicine for Elderly Diabetes Based on State Target Theory-Buyuan Zhixiao Fang in the Treatment of Elderly Patients With Diabetes and Multiple Metabolic Disorders: Study Protocol for a Multicenter, Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* 1.Age ≥65 years, irrespective of sex;\n* 2.Individuals who meet the Western medical diagnostic criteria for type 2 diabetes mellitus (T2DM) in the elderly, with a hemoglobin A1c level of ≥7.0% in the past three months;\n* 3.Compliance with the diagnostic criteria for abdominal obesity (waist circumference ≥90 cm for males and ≥85 cm for females);\n* 4.Conformity to the diagnostic standards for hypertension (systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg);\n* 5.A history of dyslipidemia, where lipid levels have not reached the general control standards for elderly individuals with T2DM following oral lipid-lowering therapy (statins\u002Fbile acid sequestrants): LDL cholesterol \\\u003C2.6 mmol\u002FL and\u002For triglycerides \\\u003C2.5 mmol\u002FL;\n* 6.Diagnosis of kidney deficiency and blood stasis according to traditional Chinese medicine, with the pattern type referring to the《Guidelines for Clinical Research of New Chinese Medicines》;\n* 7.Willingness to sign an informed consent document.\n\nExclusion Criteria:\n\n* 1.Exclusion of individuals who, within the past week, have experienced severe infections, acute cardiovascular or cerebrovascular events (such as acute cerebral infarction or myocardial infarction), significant trauma, acute pancreatitis, or other conditions that could precipitate stress-induced hyperglycemia. This also extends to those with concurrent endocrinopathies that may induce insulin resistance, such as Cushing's syndrome, hyperthyroidism, or pituitary growth hormone adenomas, as well as those currently receiving treatment with glucocorticoids or undergoing chemotherapy for malignancies.\n* 2.Exclusion of individuals with a history of neurological disorders or psychiatric conditions that could impair cognitive function, as well as those with a history of medication use for these conditions.\n* 3.Exclusion of individuals with severe complications of diabetes such as diabetic nephropathy in the uremic stage, or those with significant primary diseases of the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems, as well as individuals diagnosed with cancer.\n* 4.Exclusion of individuals with communication barriers that could affect the assessment of cognitive function, including severe impairments in speech, vision, and hearing.\n* 5.Individuals who have participated in other pharmacological clinical trials within the past month.\n* 6.Individuals who have insufficient understanding of this study, are unwilling to participate, or, based on the researchers' judgment, present a reduced likelihood of enrollment or poor compliance due to unstable work and living locations or other factors that could lead to loss to follow-up.",{"count":715,"type":22},240,[25],"The primary objective of this clinical trial is to assess the clinical efficacy and safety of the Buyuan Zhixiao Formula in treating elderly patients with diabetes and multiple metabolic disorders exhibiting symptoms of renal deficiency and blood stasis. Furthermore, this study aims to intervene in high-risk factors to prevent arteriosclerosis and to investigate the clinical efficacy of the Buyuan Zhixiao Formula in the prevention and treatment of cognitive impairments.\n\nThe main questions it aims to answer are:\n\n1. What are the clinical effects of Buyuan Zhixiao Formula, including lowering blood sugar, lowering blood pressure, lowering lipids, and treating obesity?\n2. Can Buyuan Zhixiao Formula improve cognitive impairment in diabetes? Researchers compared Buyuan Zhixiao Formula with a placebo (a drug that looks similar but contains only 10% of the active ingredients) to see if the drug Buyuan Zhixiao Formula can treat elderly people with diabetes and multiple metabolic disorders.\n\nParticipants will:\n\n1. Take the drug Bu Yuan Zhi XiaoFormula or placebo every day for 6 months；Follow-up for 6 months；\n2. Check fasting blood sugar and 2-hour postprandial blood sugar every month; check HbA1c, blood lipids, vascular function, and cognitive impairment serum markers every 3 months;\n3. Conduct scores on TCM symptoms, cognitive ability, nutritional status and other scales and adverse events;\n4. Urine and serum samples were collected before and after treatment;",[719,720,721,722,31],"Diabete Mellitus","Aging","Metabolic Disorders","Traditional Chinese Medicine","2024-06-02",{"date":725,"type":37},"2024-06-04",{"date":727,"type":22},"2024-07-06",{"date":729,"type":22},"2025-07-01",{"name":731,"class":44},"Qing Ni",{"id":733,"slug":734,"hasResults":12,"nctId":735,"briefTitle":736,"officialTitle":737,"acronym":738,"eligibilityCriteria":739,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":740,"targetDuration":4,"studyType":23,"phases":742,"briefSummary":743,"conditions":744,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":749,"lastUpdatePostDateStruct":750,"startDateStruct":752,"completionDateStruct":754,"leadSponsor":756,"locationsCount":45},"100528669","appropriate-use-of-blood-cultures-in-the-emergency-department-through-machine-learning-100528669","NCT06163781","Appropriate Use of Blood Cultures in the Emergency Department Through Machine Learning","Appropriate Use of Blood Cultures in the Emergency Department Through Machine Learning: a Randomized Controlled Trial","ABC","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Have a clinical indication for a blood culture analysis (according to the treating physician)\n* Have sufficient data recorded (laboratory results and vital sign measurements) for a prediction to be made (at least 20% of the needed parameters)\n\nExclusion Criteria:\n\n* Central Venous Line (CVL) or Peripherally Inserted Central Catheter (PICC) in situ\n* Neutrophil count \\\u003C 0.5 \\* 109\u002FL\n* Candidemia or S. aureus bacteraemia in the past 3 months.\n* Most likely diagnosis of endocarditis\u002Fspondylodiscitis\u002Finfected prosthetic material\n* Pregnant or breastfeeding patients\n* Not capable of giving informed consent",{"count":741,"type":22},7584,[25],"The goal of this clinical trial is to study whether the use of our blood culture prediction tool is non-inferior to current practice and if it can improve certain outcomes in all adult patients presenting to the emergency department with a clinical indication for a blood culture analysis (according to the treating physician). The primary endpoint is 30-day mortality. Key secondary outcomes are:\n\n* hospital admission rates\n* in-hospital mortality\n* hospital length-of-stay. In the intervention group, the physician will follow the advice of our blood culture prediction tool.\n\nIn the comparison group all patients will undergo a blood culture analysis.",[745,746,747,748,31],"Artificial Intelligence","Machine Learning","Microbiology","Emergency Service, Hospital","2024-05-03",{"date":751,"type":37},"2024-05-07",{"date":753,"type":37},"2024-02-19",{"date":755,"type":22},"2027-07",{"name":757,"class":44},"Amsterdam UMC, location VUmc"]